[
  {
    "ts": "2026-01-26T11:09:16+00:00",
    "headline": "Biogen (BIIB) Valuation Check As Shares Trade Below Analyst Targets And Long Term Returns Stay Under Pressure",
    "summary": "Recent performance snapshot Biogen (BIIB) shares closed at US$171.59, with performance mixed across recent periods. The stock shows a 1 day return of about a 1% decline, a 4.4% gain over the past week, and a 3.1% decline over the past month. Over the past 3 months, Biogen has returned 15.1%, while year to date the stock is down 3.5%. Over longer horizons, the 1 year total return is 15.3%, compared with declines of 40.0% and 38.4% over the past 3 and 5 years, respectively. See our latest...",
    "url": "https://finance.yahoo.com/news/biogen-biib-valuation-check-shares-110916369.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "a802fc6a-e789-34bd-b657-2e169552174b",
      "content": {
        "id": "a802fc6a-e789-34bd-b657-2e169552174b",
        "contentType": "STORY",
        "title": "Biogen (BIIB) Valuation Check As Shares Trade Below Analyst Targets And Long Term Returns Stay Under Pressure",
        "description": "",
        "summary": "Recent performance snapshot Biogen (BIIB) shares closed at US$171.59, with performance mixed across recent periods. The stock shows a 1 day return of about a 1% decline, a 4.4% gain over the past week, and a 3.1% decline over the past month. Over the past 3 months, Biogen has returned 15.1%, while year to date the stock is down 3.5%. Over longer horizons, the 1 year total return is 15.3%, compared with declines of 40.0% and 38.4% over the past 3 and 5 years, respectively. See our latest...",
        "pubDate": "2026-01-26T11:09:16Z",
        "displayTime": "2026-01-26T11:09:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I2k3PKJsWIEX9xgEQz8JwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmSjpFKmBAT61w1lG5.BLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-biib-valuation-check-shares-110916369.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-biib-valuation-check-shares-110916369.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-26T20:11:20+00:00",
    "headline": "Will FDA’s Priority Review of At‑Home LEQEMBI IQLIK Dosing Change Biogen’s (BIIB) Narrative",
    "summary": "Eisai and Biogen recently announced that the U.S. FDA has accepted for Priority Review a supplemental Biologics License Application for LEQEMBI IQLIK, a subcutaneous weekly autoinjector starting dose for early Alzheimer’s disease, with an FDA action date set for May 24, 2026. If approved, LEQEMBI IQLIK would be the first anti-amyloid Alzheimer’s therapy to offer at-home initiation and maintenance dosing, potentially reshaping how eligible patients begin and sustain treatment. We’ll now...",
    "url": "https://finance.yahoo.com/news/fda-priority-review-home-leqembi-201120209.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "a2af3bd3-ccbe-3102-a880-d5935cb395af",
      "content": {
        "id": "a2af3bd3-ccbe-3102-a880-d5935cb395af",
        "contentType": "STORY",
        "title": "Will FDA’s Priority Review of At‑Home LEQEMBI IQLIK Dosing Change Biogen’s (BIIB) Narrative",
        "description": "",
        "summary": "Eisai and Biogen recently announced that the U.S. FDA has accepted for Priority Review a supplemental Biologics License Application for LEQEMBI IQLIK, a subcutaneous weekly autoinjector starting dose for early Alzheimer’s disease, with an FDA action date set for May 24, 2026. If approved, LEQEMBI IQLIK would be the first anti-amyloid Alzheimer’s therapy to offer at-home initiation and maintenance dosing, potentially reshaping how eligible patients begin and sustain treatment. We’ll now...",
        "pubDate": "2026-01-26T20:11:20Z",
        "displayTime": "2026-01-26T20:11:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I2k3PKJsWIEX9xgEQz8JwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmSjpFKmBAT61w1lG5.BLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fda-priority-review-home-leqembi-201120209.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-priority-review-home-leqembi-201120209.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "ESAIY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]